Business Context and Reporting Period
This Form 8-K filing by Schweitzer-Mauduit International, Inc. (now Mativ Holdings, Inc.) is dated March 30, 2017. The report details a significant leadership transition involving the appointment of a new Chief Executive Officer (CEO) and the departure of the incumbent CEO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment agreements.
Material Changes
The primary material change is the executive leadership transition announced on March 30, 2017:
- Appointment of New CEO: Jeffrey Kramer, PhD, was named CEO, effective April 21, 2017. He will also join the Board of Directors.
- Transition Period: From April 21, 2017, through May 5, 2017, Dr. Kramer and outgoing CEO Frédéric Villoutreix will serve as Co-CEOs. Dr. Kramer will become sole CEO on May 5, 2017.
- Departure of Outgoing CEO: Frédéric Villoutreix will resign as CEO and Board member on May 5, 2017, transitioning to an independent contractor consultant role through February 28, 2018.
Compensation, Outlook, and Risks
New CEO Compensation (Dr. Kramer):
- Base Salary: $650,000 annually.
- Sign-on Bonus: $290,000 (subject to pro-rata repayment if employment ends voluntarily or for cause within four years).
- Equity: Grant of 4,500 restricted shares (2,250 vesting in one year, 2,250 in four years).
- Incentives: Annual Incentive Plan (AIP) target of 100% of base salary; Long-Term Incentive Plan (LTIP) target of 200% of base salary.
- Severance: Three times highest annual compensation upon qualifying termination following a change in control; 24 months of base salary for qualifying termination prior to a change in control.
Outgoing CEO Compensation (Mr. Villoutreix):
- Consulting Fee: $27,703 per month from May 5, 2017, through February 28, 2018.
- Lump Sum Payments: $850,000 for restrictive covenants; additional lump sum for retirement plan matching contributions.
- Equity/Incentives: Continued vesting of outstanding restricted shares; pro-rata portion of 2017 AIP and LTIP awards.
Risks and Contingencies:
- Dr. Kramer's sign-on bonus is contingent on remaining employed for four years.
- Mr. Villoutreix is subject to non-competition and non-solicitation obligations during his consulting period.
Investor Verification Checklist
- Verify the exact start date of Dr. Kramer's sole CEO tenure (May 5, 2017) versus the co-CEO transition period.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific performance metrics tied to the AIP and LTIP.
- Confirm the duration and scope of Mr. Villoutreix's consulting agreement (Exhibit 10.3) to assess potential ongoing costs.
- Check subsequent filings for the actual vesting schedule of Dr. Kramer's restricted stock and any adjustments to the sign-on bonus.